Dr Reddy’s Laboratories today announced that it has launched Decitabine for Injection (50mg), a therapeutic equivalent generic version of Dacogen® (Decitabine for Injection) in the US market on Thursday.
This follows approval by the United States Food & Drug Administration (USFDA) of Dr Reddy’s Abbreviated New Drug Application for Decitabine for Injection.
The Dacogen® brand has US sales of approximately $260 million MAT for the 12 months ending in July 2013 according to IMS Health, a release from the Hyderabad-based pharma major said.